Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

11.6%

5 terminated out of 43 trials

Success Rate

81.5%

-5.0% vs benchmark

Late-Stage Pipeline

28%

12 trials in Phase 3/4

Results Transparency

36%

8 of 22 completed with results

Key Signals

8 with results81% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (2)
P 1 (1)
P 2 (11)
P 3 (8)
P 4 (4)

Trial Status

Completed22
Unknown11
Terminated5
Recruiting2
Withdrawn2
Not Yet Recruiting1

Trial Success Rate

81.5%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (43)

Showing 20 of 20 trials
NCT02313870Phase 3CompletedPrimary

Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid

NCT00525616Phase 3CompletedPrimary

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

NCT02753777Recruiting

Autoimmune Blistering Diseases Study

NCT04563923Phase 2CompletedPrimary

Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody

NCT04206553Phase 2CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

NCT05681481Phase 3TerminatedPrimary

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT02360202Phase 4CompletedPrimary

Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid

NCT05267600Phase 2CompletedPrimary

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05984381Phase 4CompletedPrimary

Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid

NCT05906706UnknownPrimary

Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

NCT05061771Phase 3WithdrawnPrimary

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

NCT04612790Phase 3TerminatedPrimary

A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

NCT06561256CompletedPrimary

JAK Inhibitors' Efficacy in Bullous Pemphigoid

NCT04128176Phase 3WithdrawnPrimary

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

NCT06479018Not ApplicableRecruitingPrimary

Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid

NCT02837965CompletedPrimary

Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid

NCT06213909UnknownPrimary

Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis

NCT01571895Phase 2TerminatedPrimary

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

NCT05649579CompletedPrimary

Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid

NCT04728854CompletedPrimary

Telederm and Bullous Pemphigoid

Scroll to load more

Research Network

Activity Timeline